vs

Side-by-side financial comparison of Brown–Forman (BF.B) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

Brown–Forman is the larger business by last-quarter revenue ($1.0B vs $749.2M, roughly 1.4× CLOVER HEALTH INVESTMENTS, CORP.). Brown–Forman runs the higher net margin — 21.6% vs 3.6%, a 18.0% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs -5.4%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -1.6%).

Brown-Forman Corporation is an American family-controlled publicly traded company, one of the largest in the spirits and wine business. Based in Louisville, Kentucky, it manufactures several very well known brands throughout the world, including Jack Daniel's, Old Forester, Woodford Reserve, GlenDronach, BenRiach, Glenglassaugh, Herradura, Korbel, and Chambord. Brown-Forman formerly owned Southern Comfort and Tuaca before selling them off in 2016.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

BF.B vs CLOV — Head-to-Head

Bigger by revenue
BF.B
BF.B
1.4× larger
BF.B
$1.0B
$749.2M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+67.4% gap
CLOV
62.0%
-5.4%
BF.B
Higher net margin
BF.B
BF.B
18.0% more per $
BF.B
21.6%
3.6%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
-1.6%
BF.B

Income Statement — Q2 FY2026 vs Q1 FY2026

Metric
BF.B
BF.B
CLOV
CLOV
Revenue
$1.0B
$749.2M
Net Profit
$224.0M
$27.3M
Gross Margin
59.4%
Operating Margin
29.4%
3.6%
Net Margin
21.6%
3.6%
Revenue YoY
-5.4%
62.0%
Net Profit YoY
-13.2%
EPS (diluted)
$0.47
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BF.B
BF.B
CLOV
CLOV
Q1 26
$749.2M
Q4 25
$1.0B
$487.7M
Q3 25
$924.0M
$496.6M
Q2 25
$894.0M
$477.6M
Q1 25
$1.0B
$462.3M
Q4 24
$1.1B
$337.0M
Q3 24
$951.0M
$331.0M
Q2 24
$964.0M
$356.3M
Net Profit
BF.B
BF.B
CLOV
CLOV
Q1 26
$27.3M
Q4 25
$224.0M
$-49.3M
Q3 25
$170.0M
$-24.4M
Q2 25
$146.0M
$-10.6M
Q1 25
$270.0M
$-1.3M
Q4 24
$258.0M
$-22.1M
Q3 24
$195.0M
$-9.2M
Q2 24
$266.0M
$7.4M
Gross Margin
BF.B
BF.B
CLOV
CLOV
Q1 26
Q4 25
59.4%
Q3 25
59.7%
Q2 25
57.4%
Q1 25
59.8%
Q4 24
59.0%
Q3 24
59.4%
24.5%
Q2 24
59.0%
30.3%
Operating Margin
BF.B
BF.B
CLOV
CLOV
Q1 26
3.6%
Q4 25
29.4%
-10.1%
Q3 25
28.1%
-4.9%
Q2 25
22.9%
-2.2%
Q1 25
27.1%
-0.3%
Q4 24
31.1%
-6.4%
Q3 24
29.5%
-2.7%
Q2 24
38.9%
2.0%
Net Margin
BF.B
BF.B
CLOV
CLOV
Q1 26
3.6%
Q4 25
21.6%
-10.1%
Q3 25
18.4%
-4.9%
Q2 25
16.3%
-2.2%
Q1 25
26.1%
-0.3%
Q4 24
23.6%
-6.6%
Q3 24
20.5%
-2.8%
Q2 24
27.6%
2.1%
EPS (diluted)
BF.B
BF.B
CLOV
CLOV
Q1 26
$0.05
Q4 25
$0.47
Q3 25
$0.36
Q2 25
$0.31
Q1 25
$0.57
Q4 24
$0.55
Q3 24
$0.41
Q2 24
$0.56

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BF.B
BF.B
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$319.0M
$177.6M
Total DebtLower is stronger
$2.4B
Stockholders' EquityBook value
$4.1B
$339.4M
Total Assets
$8.2B
$697.7M
Debt / EquityLower = less leverage
0.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BF.B
BF.B
CLOV
CLOV
Q1 26
$177.6M
Q4 25
$319.0M
$78.3M
Q3 25
$471.0M
Q2 25
$444.0M
Q1 25
$599.0M
Q4 24
$416.0M
$194.5M
Q3 24
$416.0M
$288.0M
Q2 24
$446.0M
$254.8M
Total Debt
BF.B
BF.B
CLOV
CLOV
Q1 26
Q4 25
$2.4B
Q3 25
$2.4B
Q2 25
$2.4B
Q1 25
$2.7B
Q4 24
$2.7B
Q3 24
$2.7B
Q2 24
$2.7B
Stockholders' Equity
BF.B
BF.B
CLOV
CLOV
Q1 26
$339.4M
Q4 25
$4.1B
$308.7M
Q3 25
$4.0B
$340.9M
Q2 25
$4.0B
$344.2M
Q1 25
$3.8B
$336.1M
Q4 24
$3.7B
$341.1M
Q3 24
$3.5B
$342.2M
Q2 24
$3.5B
$324.9M
Total Assets
BF.B
BF.B
CLOV
CLOV
Q1 26
$697.7M
Q4 25
$8.2B
$541.0M
Q3 25
$8.2B
$559.7M
Q2 25
$8.1B
$575.0M
Q1 25
$8.1B
$583.7M
Q4 24
$8.3B
$580.7M
Q3 24
$8.2B
$653.0M
Q2 24
$8.2B
$674.2M
Debt / Equity
BF.B
BF.B
CLOV
CLOV
Q1 26
Q4 25
0.59×
Q3 25
0.61×
Q2 25
0.61×
Q1 25
0.70×
Q4 24
0.73×
Q3 24
0.77×
Q2 24
0.76×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BF.B
BF.B
CLOV
CLOV
Operating Cash FlowLast quarter
$132.0M
Free Cash FlowOCF − Capex
$107.0M
FCF MarginFCF / Revenue
10.3%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
0.59×
TTM Free Cash FlowTrailing 4 quarters
$610.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BF.B
BF.B
CLOV
CLOV
Q1 26
Q4 25
$132.0M
$-66.9M
Q3 25
$160.0M
$12.1M
Q2 25
$152.0M
$5.4M
Q1 25
$317.0M
$-16.3M
Q4 24
$112.0M
$34.8M
Q3 24
$17.0M
$50.0M
Q2 24
$285.0M
$44.8M
Free Cash Flow
BF.B
BF.B
CLOV
CLOV
Q1 26
Q4 25
$107.0M
$-69.0M
Q3 25
$129.0M
$11.4M
Q2 25
$102.0M
$4.8M
Q1 25
$272.0M
$-16.5M
Q4 24
$81.0M
$33.3M
Q3 24
$-24.0M
$49.6M
Q2 24
$205.0M
$44.4M
FCF Margin
BF.B
BF.B
CLOV
CLOV
Q1 26
Q4 25
10.3%
-14.1%
Q3 25
14.0%
2.3%
Q2 25
11.4%
1.0%
Q1 25
26.3%
-3.6%
Q4 24
7.4%
9.9%
Q3 24
-2.5%
15.0%
Q2 24
21.3%
12.5%
Capex Intensity
BF.B
BF.B
CLOV
CLOV
Q1 26
Q4 25
2.4%
0.4%
Q3 25
3.4%
0.1%
Q2 25
5.6%
0.1%
Q1 25
4.3%
0.0%
Q4 24
2.8%
0.5%
Q3 24
4.3%
0.1%
Q2 24
8.3%
0.1%
Cash Conversion
BF.B
BF.B
CLOV
CLOV
Q1 26
Q4 25
0.59×
Q3 25
0.94×
Q2 25
1.04×
Q1 25
1.17×
Q4 24
0.43×
Q3 24
0.09×
Q2 24
1.07×
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BF.B
BF.B

Whiskey$771.0M74%
Ready To Drink$138.0M13%
Tequila$67.0M6%
Restofportfolio$52.0M5%
Nonbrandedandbulk$8.0M1%

CLOV
CLOV

Segment breakdown not available.

Related Comparisons